Spruce Biosciences (SPRB) FCF Margin (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly FCF Margin of 2966.57% for Q4 2024, down 258005.0% year-over-year from N/an in Q1 2024, and down 92.99% quarter-over-quarter from 1537.17% in Q3 2024.
Spruce Biosciences (SPRB) FCF Margin (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported FCF Margin for 2 consecutive years, with 2966.57% the latest figure, recorded in Q4 2024.
- In Q4 2024, FCF Margin fell 258005.0% year-over-year to 2966.57%; the TTM figure through Sep 2025 stood at 892.83% (up 154678.0% YoY), while the FY2024 annual figure was 1139.56%, down 81004.0% from the prior year.
- FCF Margin eased to 2966.57% in Q4 2024 per SPRB's latest filing, from 1537.17% in the prior quarter.
- Across five years, FCF Margin topped out at 90.59% in Q2 2023 and bottomed at 2966.57% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2,966.57% |
| Sep 30, 2024 | -1,537.17% |
| Jun 30, 2024 | -689.81% |
| Mar 31, 2024 | -747.90% |
| Dec 31, 2023 | -386.52% |
| Sep 30, 2023 | -399.48% |
| Jun 30, 2023 | 90.59% |
| Mar 31, 2023 | -589.50% |